PT-141, also known as Bremelanotide, is a melanocortin receptor agonist that represents a fundamentally different approach to sexual function research — acting through the central nervous system rather than peripheral vascular mechanisms.
Research Applications
Sexual function research (CNS-mediated), melanocortin receptor signaling, hypothalamic arousal pathway studies, and hemorrhagic shock models.
Dosage Information (Research Use)
Approved clinical dose: 1.75mg subcutaneously as needed, no more than once per 24 hours. Research protocols have examined doses of 0.5-2mg. Research use only.
Reconstitution & Handling
Standard BAC water reconstitution.
Half-Life & Pharmacokinetics
Approximately 2.7 hours.
Reported Observations in Literature
Clinical trial data: nausea (most common, 40% of subjects — typically only with first dose), flushing, headache, injection site reactions. Transient blood pressure elevation reported.
Key Research References
- Clayton AH, et al. “Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women.” Obstet Gynecol. 2016 (RECONNECT trials)